Jan 11, 2021
AIM ImmunoTech Postpones Investor Conference Call. Will Reschedule for a Later Date

Jan 06, 2021
AIM ImmunoTech Announces First COVID-19-Induced Chronic Fatigue "Long Hauler" Patient Dosed with Ampligen

Dec 24, 2020
AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers

Dec 21, 2020
AIM ImmunoTech Inc.'s Drug Ampligen Awarded FDA's Orphan Drug Designation Status for the Treatment of Pancreatic Cancer

Nov 25, 2020
AIM Announces Milestone in COVID-19 Treatment and Prevention Efforts with First Patient Dosed in Study Evaluating Ampligen as Part of Combination Treatment for Patients with Cancer and COVID-19

Nov 13, 2020
AIM ImmunoTech Provides Third Quarter 2020 Business Update

Nov 02, 2020
AIM ImmunoTech Announces PLOS ONE's Publication of New Data Analyses Showing Importance of Disease Duration on Ampligen's Positive Role in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Oct 30, 2020
BioFlorida Names AIM ImmunoTech CEO Thomas K. Equels as Entrepreneur of the Year

Oct 22, 2020
AIM ImmunoTech CEO to Participate in Virtual Panel Presentation at the 23rd Annual BioFlorida Conference on October 29th

Oct 06, 2020
AIM ImmunoTech Announces IRB Approval to Enroll COVID-19 'Long Haulers' in the AMP-511 ME/CFS Clinical Trial of Ampligen

 1   2   3   4     5    6   7   8   9   10